Regeneron Reports First Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Regeneron (REGN) Misses Q1 EPS by 101c, Revenues Miss; Provides FY19 Operating Outlook
May 7, 2019 6:36 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $4.45, $1.01 worse than the analyst estimate of $5.46. Revenue for the quarter came in at $1.712 billion versus the consensus estimate of $1.76 billion.
First quarter 2019 GAAP diluted EPS was $3.99 and non-GAAP diluted EPS was $4.45First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018First quarter 2019 EYLEA® (aflibercept) Injection U.S. net sales increased 9% to $1.07 billion versus first quarter 2018First quarter 2019 EYLEA net sales outside the United States, which are recorded by the Company\'s collaborator Bayer(1), increased 7% to $669 million versus... More